Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma.
Goldwater MS, Stampfer SD, Sean Regidor B, Bujarski S, Jew S, Chen H, Xu N, Kim C, Kim S, Berenson JR. Goldwater MS, et al. Among authors: berenson jr. Clin Infect Pract. 2023 Jan;17:100214. doi: 10.1016/j.clinpr.2022.100214. Epub 2022 Dec 13. Clin Infect Pract. 2023. PMID: 36530752 Free PMC article.
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.
Berenson JR, Limon A, Rice S, Safaie T, Boccia R, Yang H, Moezi M, Lim S, Schwartz G, Eshaghian S, Brobeck M, Swift R, Eades BM, Bujarski S, Sebhat Y, Ray R, Kim S, Del Dosso A, Vescio R. Berenson JR, et al. Target Oncol. 2024 May;19(3):343-357. doi: 10.1007/s11523-024-01049-w. Epub 2024 Apr 20. Target Oncol. 2024. PMID: 38643346 Clinical Trial.
Efficacy of isatuximab in combination with steroids for the treatment of relapsed/refractory multiple myeloma patients exhibiting only biochemical progression-A single center retrospective study.
Regidor BS, Jew S, Goldwater MS, Beatty BM, Bujarski S, ElSayed A, Danis R, Kim S, Swift R, Schwartz G, Berenson JR. Regidor BS, et al. Among authors: berenson jr. Eur J Haematol. 2023 Oct;111(4):628-635. doi: 10.1111/ejh.14057. Epub 2023 Jul 24. Eur J Haematol. 2023. PMID: 37485542
Efficacy of venetoclax plus anti-CD38 monoclonal antibody-containing therapies among t(11;14) positive multiple myeloma patients regardless of timing of prior treatment with this antibody.
Regidor BS, Siddiqi D, Beatty BM, Goldwater MS, Jew S, Bujarski S, Swift R, Kim S, Berenson JR. Regidor BS, et al. Among authors: berenson jr. Eur J Haematol. 2023 Feb;110(2):222-223. doi: 10.1111/ejh.13896. Epub 2022 Nov 20. Eur J Haematol. 2023. PMID: 36367357 No abstract available.
223 results